TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

PALBOCICLIB

PALBOCICLIB
Approved 2024-06-05
Jump to: Indications Approvals Trials Competitors Safety Patents
1
Indication
--
Phase 3 Trials
1
Years on Market

Details

Status
None (Tentative Approval)
First Approved
2024-06-05
Routes
ORAL
Dosage Forms
CAPSULE, TABLET

Companies

Dr. Reddy's EUGIA PHARMA SPECLTS MSN PHARMACEUTICALS INC AIZANT DRUG RESEARCH SOLUTIONS PVT LTD ZYDUS LIFESCIENCES Sun Pharma
Active Ingredient: PALBOCICLIB

PALBOCICLIB Approval History

Loading approval history...

What PALBOCICLIB Treats

1 FDA approvals

Originally approved for its first indication in 2024 .

  • Other (1)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

PALBOCICLIB FDA Label Details

Pro

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

FDA Approval: ANDA213091 → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.